These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 16385521

  • 1. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
    Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, Maini RN.
    Arthritis Rheum; 2006 Jan; 54(1):47-53. PubMed ID: 16385521
    [Abstract] [Full Text] [Related]

  • 2. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
    Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, McClinton C, Maini RN.
    Arthritis Rheum; 2004 Apr; 50(4):1107-16. PubMed ID: 15077292
    [Abstract] [Full Text] [Related]

  • 3. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
    Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
    Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
    [Abstract] [Full Text] [Related]

  • 4. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [Abstract] [Full Text] [Related]

  • 5. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 6. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
    St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
    Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
    [Abstract] [Full Text] [Related]

  • 7. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 8. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
    Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D, St Clair EW.
    Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 10. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF.
    Ann Rheum Dis; 2009 Jul; 68(7):1153-8. PubMed ID: 18930988
    [Abstract] [Full Text] [Related]

  • 11. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 12. Infliximab in active early rheumatoid arthritis.
    Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN.
    Ann Rheum Dis; 2004 Feb; 63(2):149-55. PubMed ID: 14722203
    [Abstract] [Full Text] [Related]

  • 13. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P.
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [Abstract] [Full Text] [Related]

  • 14. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [Abstract] [Full Text] [Related]

  • 15. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [Abstract] [Full Text] [Related]

  • 16. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
    Ikeda K, Nakagomi D, Sanayama Y, Yamagata M, Okubo A, Iwamoto T, Kawashima H, Takahashi K, Nakajima H.
    J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
    [Abstract] [Full Text] [Related]

  • 17. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 18. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
    van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, van Groenendael JH, Hazes JM, Breedveld FC, Allaart CF, Dijkmans BA.
    Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 20. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
    Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C.
    J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.